Laboratory Medicine ›› 2019, Vol. 34 ›› Issue (5): 408-414.DOI: 10.3969/j.issn.1673-8640.2019.05.006
Previous Articles Next Articles
ZHENG Lan, CHENG Juan, PAN Qiuhui, YANG Lin()
Received:
2018-05-04
Online:
2019-05-30
Published:
2019-05-28
CLC Number:
ZHENG Lan, CHENG Juan, PAN Qiuhui, YANG Lin. Role of the avidity of Epstein-Barr virus capsid antigen-specific IgG antibodies and immunological changes among children with infectious mononucleosis[J]. Laboratory Medicine, 2019, 34(5): 408-414.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2019.05.006
组别 | 例数 | IM | 肺炎 | 急性 感染 | 肝损伤或 肝功能异常 | 白血病 | 呼吸道 感染 | EBV感染 | 扁桃 体炎 | 心脏 疾病 |
---|---|---|---|---|---|---|---|---|---|---|
婴儿组 | 241 | 26(10.8) | 83(34.4) | 21(8.7) | 31(12.9) | 3(1.3) | 7(2.9) | 3(1.3) | 0(0.0) | 14(5.8) |
幼儿组 | 424 | 180(42.4) | 49(11.5) | 33(7.8) | 12(2.8) | 20(4.7) | 16(3.8) | 11(2.6) | 10(2.4) | 8(1.9) |
学龄前期组 | 237 | 124(52.3) | 16(6.8) | 12(5.1) | 8(3.4) | 11(4.6) | 6(2.5) | 7(2.9) | 13(5.5) | 5(2.1) |
学龄期组 | 129 | 63(48.9) | 10(7.8) | 10(7.8) | 3(2.3) | 7(5.4) | 3(2.3) | 10(7.8) | 6(4.6) | 2(1.5) |
合计 | 1 031 | 393(38.1) | 158(15.3) | 76(7.4) | 54(5.2) | 41(4.0) | 32(3.1) | 31(3.0) | 29(2.8) | 29(2.8) |
组别 | 肿瘤 | 支气 管炎 | 淋巴结肿大或炎症 | 再生障碍 性贫血 | 黄疸 | 惊厥 | 川崎病 | 胃肠炎 | 嗜血细胞综合征 | 其他 |
婴儿组 | 6(2.5) | 6(2.5) | 0(0.0) | 0(0.0) | 13(5.4) | 3(1.2) | 3(1.2) | 1(0.4) | 1(0.4) | 20(8.3) |
幼儿组 | 8(1.9) | 5(1.2) | 8(1.9) | 6(1.4) | 0(0.0) | 11(2.6) | 2(0.5) | 5(1.2) | 4(0.9) | 36(8.5) |
学龄前期组 | 3(1.3) | 4(1.7) | 5(2.1) | 7(3.0) | 0(0.0) | 1(0.4) | 1(0.4) | 2(0.8) | 0(0.0) | 12(5.1) |
学龄期组 | 3(2.3) | 1(0.8) | 3(2.3) | 3(2.3) | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 5(3.9) |
合计 | 20(1.9) | 16(1.6) | 16(1.6) | 16(1.6) | 13(1.2) | 15(1.4) | 6(0.6) | 8(0.8) | 5(0.5) | 73(7.1) |
组别 | 例数 | IM | 肺炎 | 急性 感染 | 肝损伤或 肝功能异常 | 白血病 | 呼吸道 感染 | EBV感染 | 扁桃 体炎 | 心脏 疾病 |
---|---|---|---|---|---|---|---|---|---|---|
婴儿组 | 241 | 26(10.8) | 83(34.4) | 21(8.7) | 31(12.9) | 3(1.3) | 7(2.9) | 3(1.3) | 0(0.0) | 14(5.8) |
幼儿组 | 424 | 180(42.4) | 49(11.5) | 33(7.8) | 12(2.8) | 20(4.7) | 16(3.8) | 11(2.6) | 10(2.4) | 8(1.9) |
学龄前期组 | 237 | 124(52.3) | 16(6.8) | 12(5.1) | 8(3.4) | 11(4.6) | 6(2.5) | 7(2.9) | 13(5.5) | 5(2.1) |
学龄期组 | 129 | 63(48.9) | 10(7.8) | 10(7.8) | 3(2.3) | 7(5.4) | 3(2.3) | 10(7.8) | 6(4.6) | 2(1.5) |
合计 | 1 031 | 393(38.1) | 158(15.3) | 76(7.4) | 54(5.2) | 41(4.0) | 32(3.1) | 31(3.0) | 29(2.8) | 29(2.8) |
组别 | 肿瘤 | 支气 管炎 | 淋巴结肿大或炎症 | 再生障碍 性贫血 | 黄疸 | 惊厥 | 川崎病 | 胃肠炎 | 嗜血细胞综合征 | 其他 |
婴儿组 | 6(2.5) | 6(2.5) | 0(0.0) | 0(0.0) | 13(5.4) | 3(1.2) | 3(1.2) | 1(0.4) | 1(0.4) | 20(8.3) |
幼儿组 | 8(1.9) | 5(1.2) | 8(1.9) | 6(1.4) | 0(0.0) | 11(2.6) | 2(0.5) | 5(1.2) | 4(0.9) | 36(8.5) |
学龄前期组 | 3(1.3) | 4(1.7) | 5(2.1) | 7(3.0) | 0(0.0) | 1(0.4) | 1(0.4) | 2(0.8) | 0(0.0) | 12(5.1) |
学龄期组 | 3(2.3) | 1(0.8) | 3(2.3) | 3(2.3) | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 5(3.9) |
合计 | 20(1.9) | 16(1.6) | 16(1.6) | 16(1.6) | 13(1.2) | 15(1.4) | 6(0.6) | 8(0.8) | 5(0.5) | 73(7.1) |
组别 | 抗EBV-CA IgG抗体亲合力 | 抗EBV-CA IgM抗体 | EBV DNA | 异淋比例 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
例数 | 阳性 例数 | 阳性率 (%) | 例数 | 阳性 例数 | 阳性率 (%) | 例数 | 阳性 例数 | 阳性率 (%) | 例数 | 阳性 例数 | 阳性率 (%) | |
婴儿组 | 53 | 20 | 37.7 | 53 | 14 | 26.4 | 41 | 2 | 4.9 | 42 | 25 | 59.5 |
幼儿组 | 235 | 157 | 66.8 | 235 | 106 | 45.1 | 173 | 52 | 30.1 | 163 | 125 | 76.1 |
学龄前期组 | 157 | 124 | 79.0 | 157 | 102 | 65.0 | 88 | 53 | 60.2 | 116 | 93 | 80.2 |
学龄期组 | 55 | 54 | 98.2 | 55 | 46 | 83.6 | 55 | 24 | 43.6 | 53 | 45 | 84.9 |
组别 | 抗EBV-CA IgG抗体亲合力 | 抗EBV-CA IgM抗体 | EBV DNA | 异淋比例 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
例数 | 阳性 例数 | 阳性率 (%) | 例数 | 阳性 例数 | 阳性率 (%) | 例数 | 阳性 例数 | 阳性率 (%) | 例数 | 阳性 例数 | 阳性率 (%) | |
婴儿组 | 53 | 20 | 37.7 | 53 | 14 | 26.4 | 41 | 2 | 4.9 | 42 | 25 | 59.5 |
幼儿组 | 235 | 157 | 66.8 | 235 | 106 | 45.1 | 173 | 52 | 30.1 | 163 | 125 | 76.1 |
学龄前期组 | 157 | 124 | 79.0 | 157 | 102 | 65.0 | 88 | 53 | 60.2 | 116 | 93 | 80.2 |
学龄期组 | 55 | 54 | 98.2 | 55 | 46 | 83.6 | 55 | 24 | 43.6 | 53 | 45 | 84.9 |
组别 | 例数 | CD3-CD16+ CD56+NK细胞(%) | CD3-CD19+ B细胞(%) | CD3+T细胞 (%) | CD3+CD4+ T细胞(%) | CD3+CD8+ T细胞(%) | CD4+/CD8+ 比值 |
---|---|---|---|---|---|---|---|
婴儿组 | |||||||
IM | 30 | 8.53±6.55 | 19.09(11.92~26.18) | 69.62±9.10 | 38.98±12.04 | 27.01±12.75 | 1.84(0.82~2.49) |
非IM | 763 | 10.52±7.68 | 23.36(16.23~32.07)* | 61.88±14.28** | 38.53±12.17 | 20.26±9.30** | 2.03(1.43~2.87) |
幼儿组 | |||||||
IM | 141 | 8.30±3.97 | 8.58(6.03~15.15) | 78.56±8.53 | 24.50±11.23 | 47.53±16.86 | 0.41(0.26~0.98) |
非IM | 710 | 11.17±9.56** | 21.29(13.14~28.83)** | 64.38±13.62** | 33.85±11.13** | 25.20±11.52** | 1.56(1.08~2.02)** |
学龄前期组 | |||||||
IM | 98 | 8.54±5.13 | 4.47(2.95~6.51) | 83.59±9.14 | 17.15±9.16 | 58.83±17.41 | 0.22(0.15~0.41) |
非IM | 451 | 11.42±9.53** | 16.29(8.93~23.78)** | 69.73±26.55** | 31.87±11.10** | 30.29±12.99** | 1.25(0.83~1.61)** |
学龄期组 | |||||||
IM | 48 | 8.68±3.80 | 2.76(2.12~4.28) | 84.72±8.86 | 14.65±7.09 | 61.11±15.31 | 0.17(0.13~0.31) |
非IM | 605 | 12.69±11.78** | 13.65(7.23~20.13)** | 69.98±15.94** | 31.85±12.05** | 31.58±13.72** | 1.14(0.76~1.50)** |
组别 | 例数 | CD3-CD16+ CD56+NK细胞(%) | CD3-CD19+ B细胞(%) | CD3+T细胞 (%) | CD3+CD4+ T细胞(%) | CD3+CD8+ T细胞(%) | CD4+/CD8+ 比值 |
---|---|---|---|---|---|---|---|
婴儿组 | |||||||
IM | 30 | 8.53±6.55 | 19.09(11.92~26.18) | 69.62±9.10 | 38.98±12.04 | 27.01±12.75 | 1.84(0.82~2.49) |
非IM | 763 | 10.52±7.68 | 23.36(16.23~32.07)* | 61.88±14.28** | 38.53±12.17 | 20.26±9.30** | 2.03(1.43~2.87) |
幼儿组 | |||||||
IM | 141 | 8.30±3.97 | 8.58(6.03~15.15) | 78.56±8.53 | 24.50±11.23 | 47.53±16.86 | 0.41(0.26~0.98) |
非IM | 710 | 11.17±9.56** | 21.29(13.14~28.83)** | 64.38±13.62** | 33.85±11.13** | 25.20±11.52** | 1.56(1.08~2.02)** |
学龄前期组 | |||||||
IM | 98 | 8.54±5.13 | 4.47(2.95~6.51) | 83.59±9.14 | 17.15±9.16 | 58.83±17.41 | 0.22(0.15~0.41) |
非IM | 451 | 11.42±9.53** | 16.29(8.93~23.78)** | 69.73±26.55** | 31.87±11.10** | 30.29±12.99** | 1.25(0.83~1.61)** |
学龄期组 | |||||||
IM | 48 | 8.68±3.80 | 2.76(2.12~4.28) | 84.72±8.86 | 14.65±7.09 | 61.11±15.31 | 0.17(0.13~0.31) |
非IM | 605 | 12.69±11.78** | 13.65(7.23~20.13)** | 69.98±15.94** | 31.85±12.05** | 31.58±13.72** | 1.14(0.76~1.50)** |
组别 | 例数 | CD3-CD16+ CD56+NK细胞 (%) | CD3-CD19+ B细胞(%) | CD3+T细胞 (%) | CD3+CD4+ T细胞(%) | CD3+CD8+ T细胞(%) | CD4+/CD8+ 比值 |
---|---|---|---|---|---|---|---|
婴儿组 | |||||||
EBV DNA阳性 | 11 | 8.21±3.67 | 9.96(9.71~11.37) | 79.64±4.40 | 21.48±6.20 | 49.56±8.69 | 0.34(0.28~0.67) |
EBV DNA阴性 | 38 | 9.32±6.14 | 17.97(12.96~27.11)** | 68.44±9.24** | 38.88±12.25** | 26.31±12.00** | 1.89(1.01~2.49)** |
幼儿组 | |||||||
EBV DNA阳性 | 77 | 8.02±3.44 | 7.99(5.15~11.30) | 82.32±5.92 | 19.08±8.90 | 55.50±12.22 | 0.28(0.20~0.49) |
EBV DNA阴性 | 135 | 8.08±4.00 | 9.78(6.62~18.37)** | 77.08±8.91** | 26.98±10.97** | 43.91±17.25** | 0.62(0.30~1.26)** |
学龄前期组 | |||||||
EBV DNA阳性 | 74 | 6.90±3.39 | 4.32(2.62~6.10) | 86.04±5.94 | 14.62±6.83 | 63.49±12.62 | 0.20(0.14~0.31) |
EBV DNA阴性 | 76 | 9.10±4.68** | 4.89(3.45~6.45) | 82.99±8.52* | 19.71±8.26** | 56.06±15.75** | 0.31(0.19~0.49)** |
学龄期组 | |||||||
EBV DNA阳性 | 39 | 6.93±2.61 | 2.64(1.88~4.55) | 88.02±6.14 | 13.15±7.02 | 66.30±11.37 | 0.16(0.13~0.24) |
EBV DNA阴性 | 52 | 9.22±5.34** | 3.35(2.26~5.69) | 84.63±8.11* | 16.80±7.25* | 58.84±14.22** | 0.23(0.16~0.42)** |
组别 | 例数 | CD3-CD16+ CD56+NK细胞 (%) | CD3-CD19+ B细胞(%) | CD3+T细胞 (%) | CD3+CD4+ T细胞(%) | CD3+CD8+ T细胞(%) | CD4+/CD8+ 比值 |
---|---|---|---|---|---|---|---|
婴儿组 | |||||||
EBV DNA阳性 | 11 | 8.21±3.67 | 9.96(9.71~11.37) | 79.64±4.40 | 21.48±6.20 | 49.56±8.69 | 0.34(0.28~0.67) |
EBV DNA阴性 | 38 | 9.32±6.14 | 17.97(12.96~27.11)** | 68.44±9.24** | 38.88±12.25** | 26.31±12.00** | 1.89(1.01~2.49)** |
幼儿组 | |||||||
EBV DNA阳性 | 77 | 8.02±3.44 | 7.99(5.15~11.30) | 82.32±5.92 | 19.08±8.90 | 55.50±12.22 | 0.28(0.20~0.49) |
EBV DNA阴性 | 135 | 8.08±4.00 | 9.78(6.62~18.37)** | 77.08±8.91** | 26.98±10.97** | 43.91±17.25** | 0.62(0.30~1.26)** |
学龄前期组 | |||||||
EBV DNA阳性 | 74 | 6.90±3.39 | 4.32(2.62~6.10) | 86.04±5.94 | 14.62±6.83 | 63.49±12.62 | 0.20(0.14~0.31) |
EBV DNA阴性 | 76 | 9.10±4.68** | 4.89(3.45~6.45) | 82.99±8.52* | 19.71±8.26** | 56.06±15.75** | 0.31(0.19~0.49)** |
学龄期组 | |||||||
EBV DNA阳性 | 39 | 6.93±2.61 | 2.64(1.88~4.55) | 88.02±6.14 | 13.15±7.02 | 66.30±11.37 | 0.16(0.13~0.24) |
EBV DNA阴性 | 52 | 9.22±5.34** | 3.35(2.26~5.69) | 84.63±8.11* | 16.80±7.25* | 58.84±14.22** | 0.23(0.16~0.42)** |
[1] | LADELL K,DORNER M,ZAUNER L,et al.Immune activation suppresses initiation of lytic Epstein-Barr virus infection[J]. Cell Microbiol,2007,9(8):2055-2069. |
[2] | YAJIMA M,IMADOME K,NAKAGAWA A,et al.A new humanized mouse model of Epstein-Barr virus infection that reproduces persistent infection,lymphoproliferative disorder, and cell-mediated and humoral immune responses[J]. J Infect Dis,2008,198(5):673-682. |
[3] | 胡亚美. 诸福棠实用儿科学[M]. 8版. 北京:人民卫生出版社,2015:916-921. |
[4] | 刘立飞,周凯,胡静. 不同年龄段儿童原发性EB病毒感染发病的临床特点[J]. 实用医学杂志,2017,33(9):1471-1474. |
[5] | 马展,张泓. 儿童EB病毒感染的实验室诊断[J]. 中华检验医学杂志,2015,38(4):223-225. |
[6] | ROBERTSON P,BEYNON S,WHYBIN R,et al.Measurement of EBV-IgG anti-VCA avidity aids the early and reliable diagnosis of primary EBV infection[J]. J Med Virol,2003,70(4):617-623. |
[7] | 谢正德,刘亚谊,张辉,等. 抗体亲合力检测对诊断儿童EBV相关性传染性单核细胞增多症的意义[J]. 临床检验杂志,2005,23(5):367-368. |
[8] | DE MATTEO E,BARÓ N A V,CHABAY P,et al. Comparison of Epstein-Barr virus presence in Hodgkin lymphoma in pediatric versus adult Argentine patients[J]. Arch Pathol Lab Med,2003,127(10):1325-1329. |
[9] | 张旭. EB病毒检测及其临床应用的研究进展[J]. 检验医学,2018,33(3):259-263. |
[10] | WEISS E R,ALTER G,OGEMBO J G,et al. High Epstein-Barr virus load and genomic diversity are associated with generation of gp350-specific neutralizing antibodies following acute infectious mononucleosis[J]. J Virol,2016,91(1):pii:e01562-16. |
[11] | 孙建军,卢洪洲. 传染性单核细胞增多症的研究进展[J]. 诊断学理论与实践,2009,8(2):205-207. |
[12] | 肖楠阳,陈骐,蔡少丽. Epstein-Barr病毒的免疫调控与逃逸机制[J]. 微生物学报,2016,56(1): 19-25. |
[13] | 王颖超,朱桂英,张秋堂,等. 传染性单核细胞增多症和慢性活动性EB病毒感染患儿免疫功能分析[J]. 中国全科医学,2017,20(17):2089-2093. |
[14] | SHIBAYAMA H,IMADOME K I,ONOZAWA E,et al.Virus-specific cytotoxic T cells in chronic active Epstein-Barr virus infection[J]. Rinsho Ketsueki,2017,58(6):583-588. |
[15] | 王楠楠,刘德云. 传染性单核细胞增多症患儿细胞免疫功能的变化及意义[J]. 实用临床医药杂志,2016,20(9):199-200. |
[16] | AL TABAA Y,TUAILLON E,JEZIORSKI E,et al.B-cell polyclonal activation and Epstein-Barr viral abortive lytic cycle are two key features in acute infectious mononucleosis[J]. J Clin Virol,2011,52(1) :33-37. |
[17] | ABBOTT R J,PACHNIO A,PEDROZA-PACHECO I,et al. Asymptomatic primary infection with Epstein-Barr virus:observations on young adult cases[J]. J Virol,2017,91(21):pii:e00382-17. |
[18] | 孙志惠,刘鹏. EB病毒血清学及DNA联合检测在婴幼儿传染性单核细胞增多症临床应用研究[J]. 中国实验诊断学,2015,19(10):1696-1698. |
[1] | ZHANG Na, NIU Weihua, SUN Yuanyuan, JIA Mei. CMV and EBV co-infection affecting patient prognosis after hematopoietic stem cell transplantation [J]. Laboratory Medicine, 2023, 38(8): 760-765. |
[2] | GUO Shuang, LIU Hongli, LI Ya. Progression of migration and invasion-related miRNA and lncRNA in Epstein-Barr virus-associated gastric cancer [J]. Laboratory Medicine, 2023, 38(10): 987-996. |
[3] | WANG Xiaoyu, SEMIRE Ainiwaer, LI Shijun. Influence of specimen state on the accuracy of plasma Epstein-Barr virus DNA determination results [J]. Laboratory Medicine, 2022, 37(7): 615-617. |
[4] | YU Lisha, YANG Huijie, YIN Xuerui, GE Hanyu, WANG Huiyan, ZHENG Xiaoqun. Application role of human gamma interferon-induced protein 16 in childhood infectious mononucleosis [J]. Laboratory Medicine, 2021, 36(9): 906-908. |
[5] | ZHANG Li, ZHU Hongsheng, MA Jun, JIN Yi, SHEN Donghua. Diagnostic role of combined detection of serum ADA and LDH and the percentage of lymphocyte subsets in peripheral blood in infectious mononucleosis [J]. Laboratory Medicine, 2020, 35(9): 881-884. |
[6] | YAN Jianghong, JA Li, LI Wenhui, YANG Shuo, YAN Xiaotong, ZHAO Mengchuan, GUO Weiwei, LIU Yingye, LIU Zehao, WANG Le. Epidemiological characteristics of EB virus infection in inpatients from Hebei Children's Hospital [J]. Laboratory Medicine, 2020, 35(4): 323-326. |
[7] | ZHANG Minjie, GAO Yufang, YANG Feifei, XU Xiaoli. Meta analysis on the positive detection rate of anti-Epstein-Barr virus antibodies in Chinese population with infectious mononucleosis [J]. Laboratory Medicine, 2020, 35(3): 214-223. |
[8] | ZHANG Han, ZHANG Chaoyan, XIE Qiuxia, TIAN Jianhui. Analysis on the results of Epstein-Barr virus antibody combined determination in healthy subjects of Beijing [J]. Laboratory Medicine, 2020, 35(3): 247-250. |
[9] | ZHANG Minjie, GAO Yufang. Relationship between the levels of anti-nuclear antibodies and Epstein-Barr virus antibodies [J]. Laboratory Medicine, 2018, 33(5): 416-420. |
[10] | RONG Tingting, WANG Weiwei, WANG Juanjuan, ZHANG Lihua, SHEN Lisong. Characteristics of lymphocyte subsets and Epstein-Barr virus DNA load in children with Epstein-Barr virus infection [J]. Laboratory Medicine, 2018, 33(4): 285-289. |
[11] | ZHANG Xu. Research progress of Epstein-Barr virus determination and its clinical application [J]. Laboratory Medicine, 2018, 33(3): 259-263. |
[12] | XU Jian, WU Rong, XIANG Fenfen, ZHAN Yueping, NI Zhenhua, HAO Wenbin, YUE Honghong, KANG Xiangdong. Advantages of HLA genotypes in EBV reactivation [J]. Laboratory Medicine, 2017, 32(6): 535-539. |
[13] | WANG Xueliang, LIU Fen, JIANG Lingli, XIAO Yanqun, WANG Hualiang. Development and application of quality control materials for EBV nucleic acid determination [J]. Laboratory Medicine, 2015, 30(11): 1078-1082. |
[14] | WU Ziwen. Changes of leukocytes scatter plot in children with infectious mononucleosis [J]. , 2012, 27(3): 210-212. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||